Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$558.88+18.88 (+3.50%)
Close on Oct 30, 2026Market cap $141.65BP/E 32.5Yield –
Earnings
Vertex Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 2, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$3.33B
+12.5% on a year earlier
Non-GAAP, Q2 FY2026
$4.73
$4.52 a year earlier
Latest guidance
Raised
Aug 3, 2026 · 5 items
Quarterly results
Revenue and earnings per share from each of Vertex Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 2, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 3, 2026during market hours | $3.33B | +12.5% | $4.31 | $4.73 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 4, 2026during market hours | $2.99B | +7.8% | $4.02 | $4.47 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 12, 2026during market hours | $3.19B | +9.5% | $4.65 | $5.03 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025during market hours | – | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025during market hours | $2.96B | +11.7% | $3.99 | $4.52 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025during market hours | $2.77B | +3.0% | $2.49 | $4.06 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 10, 2025during market hours | $2.91B | +15.6% | $3.50 | $3.98 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024during market hours | $2.77B | +11.7% | $4.01 | $4.38 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024during market hours | $2.65B | +6.4% | -$13.92 | -$12.83 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024during market hours | $2.69B | +13.5% | $4.21 | $4.76 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 5, 2024during market hours | $2.52B | +9.6% | $3.71 | $4.20 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023during market hours | $2.48B | +6.4% | $3.97 | $4.08 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023during market hours | $2.49B | +13.2% | $3.52 | $3.89 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 1, 2023during market hours | $2.37B | +13.0% | $2.69 | $3.05 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 7, 2023during market hours | $2.30B | +11.0% | $3.15 | $3.76 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 27, 2022during market hours | $2.33B | +17.4% | $3.59 | $4.01 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $2.20B | – | $3.13 | $3.60 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | $2.10B | – | $2.96 | $3.52 | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 26, 2022during market hours | $2.07B | – | $3.00 | $3.37 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021during market hours | $1.98B | – | $3.28 | $3.56 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 1, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020during market hours | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 30, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Vertex Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total revenue | FY2026 | $13.10B – $13.20B | $12.95B – $13.10B | Raised | Aug 3, 2026 |
| Combined GAAP R&D, AIPR&D and SG&A expensesGAAP | FY2026 | $6.30B – $6.45B | $6.30B – $6.45B | Reaffirmed | Aug 3, 2026 |
| Combined non-GAAP R&D, AIPR&D and SG&A expensesnon-GAAP | FY2026 | $5.65B – $5.75B | $5.65B – $5.75B | Reaffirmed | Aug 3, 2026 |
| Non-CF product revenue | FY2026 | $500.00M | – | New | May 4, 2026 |
| Non-GAAP effective tax ratenon-GAAP | FY2026 | 19.5% – 20.5% | 19.5% – 20.5% | Reaffirmed | Aug 3, 2026 |
Guidance history
Every forecast Vertex Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 3, 2026 | Non-GAAP effective tax rate | FY2026 | 19.5% – 20.5% | Reaffirmed |
| Aug 3, 2026 | Combined GAAP R&D, AIPR&D and SG&A expenses | FY2026 | $6.30B – $6.45B | Reaffirmed |
| Aug 3, 2026 | Combined non-GAAP R&D, AIPR&D and SG&A expenses | FY2026 | $5.65B – $5.75B | Reaffirmed |
| Aug 3, 2026 | Total revenue | FY2026 | $13.10B – $13.20B | Raised |
| Aug 3, 2026 | non-CF products | FY2026 | $500.00M | Lowered |
| May 4, 2026 | Non-GAAP effective tax rate | FY2026 | 19.5% – 20.5% | Reaffirmed |
| May 4, 2026 | Non-CF product revenue | FY2026 | $500.00M | New |
| May 4, 2026 | Combined GAAP R&D, AIPR&D and SG&A expenses | FY2026 | $6.30B – $6.45B | Reaffirmed |
| May 4, 2026 | Combined non-GAAP R&D, AIPR&D and SG&A expenses | FY2026 | $5.65B – $5.75B | Reaffirmed |
| May 4, 2026 | Total revenue | FY2026 | $12.95B – $13.10B | Raised |
| Feb 12, 2026 | Non-GAAP effective tax rate | FY2026 | 19.5% – 20.5% | New |
| Feb 12, 2026 | Combined GAAP R&D, AIPR&D and SG&A expenses | FY2026 | $6.30B – $6.45B | New |
| Feb 12, 2026 | Combined non-GAAP R&D, AIPR&D and SG&A expenses | FY2026 | $5.65B – $5.75B | New |
| Feb 12, 2026 | Total revenue | FY2026 | $12.95B – $13.10B | New |
| Feb 12, 2026 | Non-CF product revenue | FY2026 | $500.00M | Lowered |
| Nov 3, 2025 | Total revenue | FY2025 | $11.90B – $12.00B | Raised |
| Aug 4, 2025 | Non-GAAP effective tax rate | FY2025 | 20.5% – 21.5% | New |
| Aug 4, 2025 | Combined GAAP R&D, AIPR&D and SG&A expenses | FY2025 | $5.55B – $5.70B | New |
| Aug 4, 2025 | Combined non-GAAP R&D, AIPR&D and SG&A expenses | FY2025 | $4.90B – $5.00B | New |
| Aug 4, 2025 | Total revenue | FY2025 | $11.85B – $12.00B | New |
| May 5, 2025 | Combined GAAP R&D, AIPR&D and SG&A expenses | FY2025 | $5.55B – $5.70B | Reaffirmed |
| May 5, 2025 | Combined Non-GAAP R&D, AIPR&D and SG&A expenses | FY2025 | $4.90B – $5.00B | Reaffirmed |
| May 5, 2025 | Non-GAAP effective tax rate | FY2025 | 20.5% – 21.5% | Reaffirmed |
| May 5, 2025 | Total revenue | FY2025 | $11.85B – $12.00B | Raised |
| Feb 10, 2025 | Combined GAAP R&D, AIPR&D and SG&A expenses | FY2025 | $5.55B – $5.70B | New |
| Feb 10, 2025 | Non-GAAP effective tax rate | FY2025 | 20.5% – 21.5% | New |
| Feb 10, 2025 | Combined Non-GAAP R&D, AIPR&D and SG&A expenses | FY2025 | $4.90B – $5.00B | New |
| Feb 10, 2025 | Total revenue | FY2025 | $11.75B – $12.00B | New |
| Nov 4, 2024 | Non-GAAP effective tax rate | FY2024 | 90% | Lowered |
| Nov 4, 2024 | AIPR&D expenses | FY2024 | $4.60B | Reaffirmed |
| Nov 4, 2024 | Combined Non-GAAP R&D and SG&A expenses | FY2024 | $4.20B – $4.30B | Reaffirmed |
| Nov 4, 2024 | product revenue | FY2024 | $10.80B – $10.90B | Raised |
| Aug 1, 2024 | Non-GAAP effective tax rate | FY2024 | 100% | Raised |
| Aug 1, 2024 | AIPR&D expenses | FY2024 | $4.60B | New |
| Aug 1, 2024 | Combined GAAP R&D and SG&A expenses | FY2024 | $5.00B – $5.20B | Raised |
| Aug 1, 2024 | combined Non-GAAP R&D and SG&A expenses | FY2024 | $4.20B – $4.30B | Lowered |
| Aug 1, 2024 | product revenue | FY2024 | $10.65B – $10.85B | Raised |
| May 6, 2024 | Non-GAAP effective tax rate | FY2024 | 20% – 21% | Reaffirmed |
| May 6, 2024 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses | FY2024 | $4.90B – $5.10B | Reaffirmed |
| May 6, 2024 | combined Non-GAAP R&D, Acquired IPR&D and SG&A expense | FY2024 | $4.30B – $4.40B | Reaffirmed |
| May 6, 2024 | product revenue | FY2024 | $10.55B – $10.75B | Reaffirmed |
| Feb 5, 2024 | Non-GAAP effective tax rate | FY2024 | 20% – 21% | New |
| Feb 5, 2024 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses | FY2024 | $4.90B – $5.10B | New |
| Feb 5, 2024 | Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses | FY2024 | $4.30B – $4.40B | New |
| Feb 5, 2024 | Total product revenues | FY2024 | $10.55B – $10.75B | New |
| Nov 6, 2023 | Non-GAAP effective tax rate | FY2023 | 20% – 21% | Lowered |
| Nov 6, 2023 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses | FY2023 | $4.55B – $4.80B | Reaffirmed |
| Nov 6, 2023 | Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses | FY2023 | $4.10B – $4.20B | Reaffirmed |
| Nov 6, 2023 | CF product revenue | FY2023 | $9.85B | Raised |
| Aug 1, 2023 | Non-GAAP effective tax rate | FY2023 | 21% – 22% | Reaffirmed |
| Aug 1, 2023 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses | FY2023 | $4.55B – $4.80B | Raised |
| Aug 1, 2023 | Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses | FY2023 | $4.10B – $4.20B | Raised |
| Aug 1, 2023 | CF product revenue | FY2023 | $9.70B – $9.80B | Raised |
| May 1, 2023 | Non-GAAP effective tax rate | FY2023 | 21% – 22% | Reaffirmed |
| May 1, 2023 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses | FY2023 | $4.35B – $4.60B | Reaffirmed |
| May 1, 2023 | Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses | FY2023 | $3.90B – $4.00B | Reaffirmed |
| May 1, 2023 | CF product revenue | FY2023 | $9.55B – $9.70B | Reaffirmed |
| Feb 7, 2023 | Non-GAAP effective tax rate | FY2023 | 21% – 22% | New |
| Feb 7, 2023 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses (3) | FY2023 | $4.35B – $4.60B | New |
| Feb 7, 2023 | Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses (3) | FY2023 | $3.90B – $4.00B | New |
| Feb 7, 2023 | CF product revenues | FY2023 | $9.55B – $9.70B | New |
| Oct 27, 2022 | Non-GAAP effective tax rate | FY2022 | 21% – 22% | Reaffirmed |
| Oct 27, 2022 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses | FY2022 | $3.48B – $3.63B | Reaffirmed |
| Oct 27, 2022 | Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses | FY2022 | $3.00B – $3.10B | Reaffirmed |
| Oct 27, 2022 | Product revenues | FY2022 | $8.80B – $8.90B | Raised |
| Aug 4, 2022 | Non-GAAP effective tax rate | FY2022 | 21% – 22% | Reaffirmed |
| Aug 4, 2022 | Combined GAAP R&D, Acquired IPR&D and SG&A expenses | FY2022 | $3.48B – $3.63B | Raised |
| Aug 4, 2022 | Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses | FY2022 | $3.00B – $3.10B | Raised |
| Aug 4, 2022 | product revenue | FY2022 | $8.60B – $8.80B | Raised |
| May 5, 2022 | Non-GAAP effective tax rate | FY2022 | 21% – 22% | Reaffirmed |
| May 5, 2022 | Combined GAAP R&D and SG&A expenses | FY2022 | $3.30B – $3.45B | Reaffirmed |
| May 5, 2022 | Combined Non-GAAP R&D and SG&A expenses | FY2022 | $2.82B – $2.92B | Raised |
| May 5, 2022 | product revenue | FY2022 | $8.40B – $8.60B | Reaffirmed |
| Jan 26, 2022 | Non-GAAP effective tax rate | FY2022 | 21% – 22% | New |
| Jan 26, 2022 | Combined GAAP R&D and SG&A expenses (2) | FY2022 | $3.30B – $3.45B | New |
| Jan 26, 2022 | Combined Non-GAAP R&D and SG&A expenses (2) | FY2022 | $2.70B – $2.75B | New |
| Jan 26, 2022 | Product revenues | FY2022 | $8.40B – $8.60B | New |
| Nov 2, 2021 | Non-GAAP effective tax rate | FY2021 | 21% – 22% | New |
| Nov 2, 2021 | Combined GAAP R&D and SG&A expenses | FY2021 | $3.80B – $3.95B | New |
| Nov 2, 2021 | Combined Non-GAAP R&D and SG&A expenses | FY2021 | $2.25B – $2.30B | New |
| Nov 2, 2021 | Product revenues | FY2021 | $7.40B – $7.50B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Vertex Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results